BMC nephrology · 2026
Hematological parameter dynamics in critically ill patients treated with oXiris®-based CRRT and CytoSorb® hemoadsorption: a prospective single-center study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Špirić Nikolina, Vučićević Katarina, Villar Jesús, Kovačević Tijana, Dragić Saša, Zlojuto Biljana, Momčičević Danica, Jandrić Milka, Klječanin Grozdana, Kovačević Pedja
Аннотация
BACKGROUND: Hemoadsorption is increasingly used as adjunctive extracorporeal support in sepsis and septic shock. Comparative data on device-specific hematologic effects remain limited. CytoSorb® and oXiris® are among the most widely applied hemoadsorption devices, but their impact on blood element kinetics has not been fully characterized.
METHODS: In a prospective single-center observational study, 66 patients with sepsis or septic shock underwent hemoadsorption combined with continuous renal replacement therapy (CRRT) using either CytoSorb® (n = 36) or oXiris® (n = 30). Hemoglobin (Hb), hematocrit (Hct), erythrocytes (RBC), and platelets (PLT) were measured prior to and following hemoadsorption. Descriptive analyses and statistical tests were employed to evaluate between-group differences in hematologic parameters. Clinically relevant declines defined as ≥ 15% reduction in Hb, Hct, and RBC, and ≥ 50% in PLT were treated as events in time-to-event (TTE) analysis.
RESULTS: CytoSorb® was associated with significant reductions in Hb, Hct, RBC, and PLT, while no statistically significant hematologic changes were observed with oXiris®. TTE analyses showed that CytoSorb® led to faster declines across all parameters in reaching predefined reductions. Median times to predefined thresholds ranged from 19.6 to 27.6 h with CytoSorb®, compared with 38.9 to 42.1 h with oXiris®, despite shorter treatment duration in the CytoSorb® group.
CONCLUSION: CytoSorb® hemoadsorption results in more pronounced and faster hematologic deterioration compared with oXiris®, indicating meaningful device-specific differences in blood element kinetics during extracorporeal therapy. Close hematologic monitoring is particularly important when CytoSorb® is used. Larger multicenter studies with mechanistic biomarkers are needed to validate these findings.
METHODS: In a prospective single-center observational study, 66 patients with sepsis or septic shock underwent hemoadsorption combined with continuous renal replacement therapy (CRRT) using either CytoSorb® (n = 36) or oXiris® (n = 30). Hemoglobin (Hb), hematocrit (Hct), erythrocytes (RBC), and platelets (PLT) were measured prior to and following hemoadsorption. Descriptive analyses and statistical tests were employed to evaluate between-group differences in hematologic parameters. Clinically relevant declines defined as ≥ 15% reduction in Hb, Hct, and RBC, and ≥ 50% in PLT were treated as events in time-to-event (TTE) analysis.
RESULTS: CytoSorb® was associated with significant reductions in Hb, Hct, RBC, and PLT, while no statistically significant hematologic changes were observed with oXiris®. TTE analyses showed that CytoSorb® led to faster declines across all parameters in reaching predefined reductions. Median times to predefined thresholds ranged from 19.6 to 27.6 h with CytoSorb®, compared with 38.9 to 42.1 h with oXiris®, despite shorter treatment duration in the CytoSorb® group.
CONCLUSION: CytoSorb® hemoadsorption results in more pronounced and faster hematologic deterioration compared with oXiris®, indicating meaningful device-specific differences in blood element kinetics during extracorporeal therapy. Close hematologic monitoring is particularly important when CytoSorb® is used. Larger multicenter studies with mechanistic biomarkers are needed to validate these findings.